Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 13, 2018
UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
RA’ANANA, Israel and NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
June 13, 2018
Vermillion Names Chris Goulart to Senior Vice President of Commercial Operations
AUSTIN, Texas, June 13, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Mr. Chris Goulart ...
June 13, 2018
OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting
NANTES, France, June 13, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) announces that all the resolutions submitted to a vote at the Combined General ...
June 12, 2018
Kuros Biosciences Announces Start of Randomized Controlled Trial of MagnetOs in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, June 12, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) announced today that the University Medical Center Utrecht (UMCU) in the Netherlands has ...
June 12, 2018
Galmed's 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study
Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral, once-daily, liver-targeted SCD1 modulator, for ...
June 12, 2018
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA ...
June 12, 2018
CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility
MONMOUTH JUNCTION, N.J., June 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
June 12, 2018
Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference
WARREN, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will ...
June 12, 2018
Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
NEW YORK, June 12, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and ...
June 12, 2018
STRATA Skin Sciences to Present at JMP 2018 Life Sciences Conference
HORSHAM, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, ...
June 12, 2018
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced ...
June 12, 2018
FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
BOSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
June 11, 2018
AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on prolonging healthspan through an understanding of the fundamental mechanisms of human ...
June 11, 2018
MediWound Completes Enrollment in NexoBrid® U.S. Phase 3 DETECT Study
YAVNE, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
June 11, 2018
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
VANCOUVER, June 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral ...
June 11, 2018
Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
June 11, 2018
INVENTIVA to Present at the 2018 JMP Securities Life Sciences Conference
Daix (France), June 11, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) ...
June 11, 2018
Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Jayson Dallas, M.D., as ...
June 11, 2018
Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo®
SAN DIEGO, June 11, 2018 (GLOBE NEWSWIRE) -- Pfenex (NYSE American:PFNX) and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize ...
June 8, 2018
BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was ...
Page 54 of 138